Peptide Mapping: Confirming Sequence, Not Just Mass

A peptide map confirms sequence by cutting the peptide at predictable positions, separating the pieces, and measuring each piece's mass and fragmentation pattern. Each fragment must match a stretch of the expected sequence, and together the fragments must cover the whole chain. A single intact mass cannot do this, because every rearrangement of the same residues has the same mass; the handbook's article on mass spectrometry and identity explains that limitation. This page covers the method that answers it: how a map is designed, run and reported.

For a short synthetic peptide the digestion step is often unnecessary. A 20-residue chain can usually be fragmented whole in a tandem mass spectrometer, and the fragment ladder read directly. Mapping by enzymatic digestion becomes the better route for longer chains, for locating disulfide bonds and modifications, and for comparing batches against a reference. The European guideline on synthetic peptides states the same division: peptide mapping may be applicable for longer peptides where tandem MS sequencing data are difficult to obtain 5.

Three routes to sequence

Tandem mass spectrometry works the same way in the second and third routes: a precursor ion is isolated and broken, and the masses of the fragments are recorded 3. Collision-induced dissociation cleaves the backbone amide bonds and gives b ions, which carry the N-terminus, and y ions, which carry the C-terminus. Electron-transfer dissociation cleaves a different backbone bond, gives c and z ions, works best on higher charge states and tends to leave labile modifications attached 2. The mass differences between consecutive fragments in a series identify the residues in order.

Choosing the enzyme

The enzyme sets where the chain is cut and therefore what the map can see. Trypsin is the default because its specificity is narrow and well characterised: high-accuracy mass spectrometric data showed it cleaves C-terminal to lysine and arginine and not elsewhere 1. Cleavage is typically slowed or blocked where proline follows the lysine or arginine. The tryptic fragments of most sequences carry a basic residue at the C-terminus, which ionises well and gives clean y-ion series.

Always digest the sequence on paper first. Take a generic 20-residue peptide, AGSKLEPVRNWTFGDKLAYR. Trypsin cuts after K4, R9 and K16 and gives four pieces: AGSK, LEPVR, NWTFGDK and LAYR. Two of those are four residues long and one of them is small and polar; on a C18 column in 0.1% acid, a fragment such as AGSK may elute in or near the void and be lost among solvent peaks. A tryptic map of this peptide could report full coverage on paper and miss a quarter of the sequence in practice.

The four tryptic pieces also do not, by themselves, fix their own order: four correct fragments could in principle come from a peptide assembled in a different order. A second enzyme closes that gap. Asp-N cuts before D15 and gives AGSKLEPVRNWTFG and DKLAYR. The second piece spans the junction between NWTFGDK and LAYR, and the first spans the junctions between the first three tryptic pieces. Overlapping fragments from two digests are what turn fragment identities into a sequence.

Running the digest

1. Write the purpose: full sequence confirmation, disulfide assignment, location of a modification, or comparison with a reference.
2. Digest the sequence in silico with each candidate enzyme, and list expected fragments with their monoisotopic masses and expected charge states.
3. Where the peptide contains cysteine and connectivity is not the question, reduce with dithiothreitol and alkylate with iodoacetamide; each alkylated cysteine adds 57.021 Da.
4. Where connectivity is the question, keep one aliquot non-reduced and compare its map with the reduced map.
5. Buffer at pH about 8 in a volatile salt such as ammonium bicarbonate, which is compatible with mass spectrometry.
6. Add sequencing-grade enzyme at 1:20 to 1:50 by mass to the peptide, and incubate at 37 °C for 2 to 18 hours; record the time.
7. Stop the digest by acidifying below pH 3 with formic or trifluoroacetic acid.
8. Run an enzyme-only blank, an undigested sample, and a reference material digested alongside the sample if one exists.
9. Separate by LC-MS/MS with a shallow gradient and a low-organic hold at the start, so that small polar fragments are retained.

The blank identifies enzyme autolysis fragments, which otherwise appear as unexplained peaks. The undigested sample shows how much intact peptide survives, which is a measure of digestion completeness. The parallel reference digest is the basis of comparative mapping, in which the test map is judged against a map generated the same day from characterised material; this is how peptide mapping is used as an identity test for biotechnological products under ICH Q6B 4.

Digest artefacts

A digest is a chemical reaction held at slightly basic pH and body temperature for hours, and it modifies the sample as well as cutting it. The artefacts need to be recognised so that they are not reported as properties of the material.

Assignment and coverage

Each peak in the map is assigned when two conditions hold: its mass matches an expected fragment within the stated tolerance, and its fragmentation spectrum contains a b- or y-ion series consistent with that stretch of sequence. A mass match alone assigns the fragment's composition, which for a four- or five-residue fragment is a much narrower claim than for an intact peptide but still not an order.

Coverage should be reported two ways. Mass coverage is the share of residues contained in fragments whose masses were found. Sequence coverage is the share of residues whose position is supported by fragment ions. The second is the meaningful figure for sequence confirmation. For a 20-residue peptide, a fragment series that confirms 19 of the 19 inter-residue bonds is complete; one that confirms 14 leaves five positions inferred rather than shown, and the report should say which.

Two limits survive any amount of mapping. Leucine and isoleucine share a formula and give identical fragment masses under standard collision methods; distinguishing them needs specialised fragmentation or orthogonal methods such as amino acid analysis. Stereochemistry is also invisible: a D-residue gives the same fragments as the L-residue. The European guideline treats both as starting-material and process risks, listing incorrect amino acids such as isoleucine in place of leucine and diastereomers among the related substances to be controlled 5.

When mapping is warranted

• The chain is long enough that tandem MS of the intact peptide leaves gaps in the fragment ladder.
• Disulfide connectivity must be assigned, not only the number of bonds.
• A modification seen as a mass shift on the intact peptide must be located to a residue.
• Two batches must be compared as fingerprints against a characterised reference.
• An impurity peak must be identified, and its intact mass fits more than one candidate structure.

Where none of these applies, tandem MS of the intact peptide with a well-annotated fragment spectrum is the proportionate choice for a 20-residue peptide. It avoids digest artefacts entirely and gives a direct ladder. The decision should be written into the method, with the reason.

The mapping report

Close the report with the sequence coverage by fragment ions, the list of positions not directly confirmed, the unassigned peaks above a stated threshold, and the leucine/isoleucine and stereochemistry caveats. A report in that form states what was shown and what was assumed, which is the whole purpose of the exercise.